

**Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

June 20, 2023: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Chief Medical Officer Updates** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
 - Data presentation: Adherence to Heart Failure Medications
 - Introduce: “Triple Therapy”: Opioids, Benzodiazepines, and Skeletal Muscle Relaxants

- **Clinical Update: Drug Reviews** **7:20-7:40**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - Rezvoglar® (interchangeable with Lantus will be reviewed in Hypoglycemics, Insulin TCR)

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Ermeza® (levothyroxine)
 - Hemgenix® (etranacogene dezaparvovec)
 - Sunlenca® (lenacapavir)
 - Tepezza® (teprotumumab-trbw)
 - Tziel® (teplizumab-mzwv)
 - Xelstrym® (dextroamphetamine)
 - Zonisade® (zonisamide)

- **New Managed Therapeutic Drug Classes** **7:40 -7:40**
 - None at this time.
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:40 - 8:20**
(Public comment prior to Board action)
 - Antifungals, Oral
 - Antifungals, Topical
 - Bone Resorption Inhibitors & Related Agents
 - Hypoglycemics, Incretin Mimetics/Enhancers & SGLT2-Inhibitors
 - Hypoglycemics, Insulin
 - Hypoglycemics, Other
 - Multiple Sclerosis Agents (new drug Briumvi® (ublituximab-xiiy) included)

- **Review of Newly Developed/Revised Criteria** **8:20 - 8:30**
(Public comment prior to Board action)
 - Continuous Glucose Monitoring
 - Opioid Use Disorder Treatment

- **General Announcements** **8:30 – 8:30**
 - None at this time.

- **Adjourn** **8:30**